GPC3 and neoplasm: Upon expansion, these anti–glypican-3 CAR Vδ1 cells exhibited minimal inhibitory receptor expression manifested by robust in vitro anti-tumor activity against hepatocellular carcinoma cells, even when in the presence of soluble glypican-3 [206, 207].